Selective Inhibition of Magnocellular Vasopressin Neurons by Hypoosmolality: Effect on Histamine- and Stress-Induced Secretion of Adrenocorticotropin and Prolactin

Kjær, Andreas; Knigge, Ulrich; Jørgensen, Henrik; Warberg, Jørgen

doi:10.1159/000054331

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nipple stimulation, light, olfaction, and stress, stimulate prolactin secretion. Other neurotransmitters and neuropeptides can also modulate PRL secretion (for example endothelin, TGF beta1, angiotensin, somatostatin, substance P, neurotensin, calcitonin, EGF, natriuretic atrial peptide, bombesin, cholecystokinin, acetylcholine, and vasopressin) [25][26][27]. Among medications that increase serum PRL, dopamine receptor antagonists such as neuroleptics (i.e., sulpiride, haloperidol, chlorpromazine, risperidone) and antiemetic drugs (i.e., metoclopramide, domperidone) can elevate serum PRL at the same range that is usually detected in prolactinoma [28].…”

Section: Prolactin Axismentioning

confidence: 99%

Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications

Biagetti

Simó

2021

IJMS

View full text Add to dashboard Cite

Prolactinoma has the highest incidence rate among patients with functional pituitary tumours. Although mostly benign, there is a subgroup that can be aggressive. Some clinical, radiological and pathology features have been associated with a poor prognostic. Therefore, it can be considered as a group of heterogeneous tumours. The aim of this paper is to give an overview of the molecular pathways involved in the behaviour of prolactinoma in order to improve our approach and gain deeper insight into the better understanding of tumour development and its management. This is essential for identifying patients harbouring aggressive prolactinoma and to establish personalised therapeutics options.

show abstract

Section: Prolactin Axismentioning

confidence: 99%

Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications

Biagetti

Simó

2021

IJMS

View full text Add to dashboard Cite

show abstract

Copeptin response to hypoglycemic stress is linked to prolactin activation in children

Drummond

Soares

Pedrosa³

et al. 2020

Pituitary

View full text Add to dashboard Cite

The Effect of the Alpha‐2‐Adrenergic Agonist, Clonidine, on Secretion Patterns and Rates of Adrenocorticotropic Hormone and its Secretagogues in the Horse

Alexander

Irvine

2000

J Neuroendocrinology

View full text Add to dashboard Cite

Alpha-2-adrenoceptor activation may lower adrenocorticotropic hormone (ACTH) by reducing secretagogue input and/or increasing the release of an inhibitory factor (CIF). To investigate this, we gave clonidine, an alpha-2-agonist, to seven horses, and collected pituitary venous blood every minute for 20 min before treatment and 40 min after treatment. Six horses were given saline vehicle. Mean secretion rates of corticotrophin-releasing hormone (CRH), arginine vasopressin (AVP) and ACTH were calculated before and during four 5-min then two 10-min periods after clonidine or saline. Reduction in ACTH secretion without corresponding changes in CRH and/or AVP would imply the presence of CIF. Secretion rates of ACTH (P = 0.008) and AVP (P = 0.0005) fell after clonidine and remained lower than baseline values for 20 min and 10 min, respectively. The CRH secretion rate decreased slightly but not significantly after clonidine. In controls, hormone secretion rates did not alter during the experiment. Multiple linear regression showed that CRH and AVP secretion accounted for 69% (treated) or 45% (controls) of the variation in ACTH secretion (P < 0.0001 for each). CRH alone contributed 80% (treated) or 76% (controls) of the fit to this model, which is consistent with the concept that CRH 'sets the gain' of the response of corticotrophs to fluctuations in AVP. Accordingly, minute-to-minute changes in pituitary concentrations of AVP and ACTH were synchronous when all data were considered (% concordant changes: controls, 68%, P < 0.0001; treated, 76%, P < 0.0001) and the percentage of concordant movement was unaffected by clonidine (before 72%; after 73%; P = 0.80). In treated horses but not controls, the ratio between the secretion rates of ACTH and AVP fell (P = 0.009), while the ACTH : CRH ratio tended to fall after clonidine, implying reduced responsiveness to stimulation. Moreover, one horse showed a drop in ACTH and a rise in CRH and AVP secretion after clonidine. We conclude that in horses alpha-2-adrenoceptor activation lowers ACTH secretion primarily by reducing the secretion of AVP and possibly CRH. While there was some evidence that a CIF may participate in the clonidine-induced suppression of ACTH, the subtlety of the discordance between ACTH and its secretagogues in most horses and the rarity of complete dissociation indicate that it does not play a major role.

show abstract

Selective Inhibition of Magnocellular Vasopressin Neurons by Hypoosmolality: Effect on Histamine- and Stress-Induced Secretion of Adrenocorticotropin and Prolactin

Cited by 4 publications

References 23 publications

Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications

Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications

Copeptin response to hypoglycemic stress is linked to prolactin activation in children

The Effect of the Alpha‐2‐Adrenergic Agonist, Clonidine, on Secretion Patterns and Rates of Adrenocorticotropic Hormone and its Secretagogues in the Horse

Contact Info

Product

Resources

About